Novo Nordisk CEO: "We are very encouraged by growth momentum"

Pharmaceutical firm Novo Nordisk’s sales growth has accelarated since 2019, when it introduced new financial targets and ambitions for 2025. A theme of the company’s capital markets day, which is taking place at the time of writing on Thursday, is how to continue on this track.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Wegovy update on Novo Nordisk's capital markets day agenda
For subscribers